Compare RKLB & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RKLB | BDX |
|---|---|---|
| Founded | 2006 | 1897 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.6B | 43.0B |
| IPO Year | 2020 | 1997 |
| Metric | RKLB | BDX |
|---|---|---|
| Price | $70.04 | $152.97 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 13 |
| Target Price | $81.62 | ★ $186.00 |
| AVG Volume (30 Days) | ★ 22.2M | 2.3M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 2.89% |
| EPS Growth | ★ 2.63 | N/A |
| EPS | N/A | ★ 0.25 |
| Revenue | $601,799,000.00 | ★ $21,840,000,000.00 |
| Revenue This Year | $48.53 | N/A |
| Revenue Next Year | $39.06 | $3.02 |
| P/E Ratio | ★ N/A | $612.64 |
| Revenue Growth | ★ 37.96 | 8.24 |
| 52 Week Low | $37.57 | $140.11 |
| 52 Week High | $150.85 | $213.08 |
| Indicator | RKLB | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 33.95 | 51.40 |
| Support Level | $64.94 | $153.27 |
| Resistance Level | $77.04 | $159.72 |
| Average True Range (ATR) | 5.09 | 3.70 |
| MACD | -0.70 | -0.22 |
| Stochastic Oscillator | 10.56 | 34.37 |
Rocket Lab Corp is engaged in space, building rockets, and spacecraft. It provides end-to-end mission services that provide frequent and reliable access to space for civil, defense, and commercial markets. It designs and manufactures the Electron and Neutron launch vehicles and Photon satellite platform. Rocket Lab's Electron launch vehicle has delivered multiple satellites to orbit for private and public sector organizations, enabling operations in national security, scientific research, space debris mitigation, Earth observation, climate monitoring, and communications. The business operates in two segments Launch Services and Space Systems. Geographically it serves Japan, and rest of the world and earns key revenue from the United States.
Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.